Captopril for Refractory Hypertension in Patients with Chronic Renal Failure and Renal Transplantation

Abstract
The converting-enzyme inhibitor, Captopril, was given to ten patients with refractory severe hypertension of renal origin: 6 patients had chronic renal failure, 3 patients had hypertension following renal transplantation, and one patient had hypertension and congestive cardiac failure. Control of blood pressure was achieved with doses from 75 to 400 mg/day. Severe hyperkalemia occurred in one patient, ageusia (dose dependent) in another, and one patient withdrew from treatment because of nausea.